Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance
The purpose of this research is to see if monitoring the brain using magnetic resonance imaging (MRI) after radiation therapy will allow investigators to find cancer that has spread to the brain (brain metastases) before it causes symptoms.
Conditions:
🦠 Brain Metastases 🦠 Nonsmall Cell Lung Cancer Stage III
🗓️ Study Start (Actual) 30 August 2023
🗓️ Primary Completion (Estimated) May 2025
✅ Study Completion (Estimated) August 2025
👥 Enrollment (Estimated) 60
🔬 Study Type INTERVENTIONAL
📊 Phase PHASE2
Locations:
📍 Winston-Salem, North Carolina, United States

📋 Eligibility Criteria

Description

    Inclusion Criteria:

    • * Age ≥ 18 years of age.
    • * Patients with non-squamous locally advanced lung cancer defined by American Joint Committee on Cancer (AJCC) version 8 stage IIIA, IIIB, or IIIC disease.
    • * Histology described as adeno-squamous or not otherwise specified favoring squamous are eligible.
    • * Patients may be enrolled before or after the start of radiation therapy but must be enrolled and have their first surveillance MRI brain at 120 +/- 10 days of their first treatment of radiation therapy for their locally advanced lung cancer. The first radiation treatment is defined as day 1.
    • * Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 3.
    • * Epidermal growth factor receptor (EGFR) \> 30 mL/min/1.73m2.
    • * Patients must be eligible for a brain MRI per the Wake Forest MRI safety screening checklist questionnaire. This will be completed by a MRI imaging technician, enrolling physician, CPDM staff member, a magnetic resonance safety officer, and/or a radiologist as indicated in the form.

    Exclusion Criteria:

    • * Known brain metastases on staging MRI.
    • * Questionable findings that may represent a differential of vasculature abnormalities/stroke/ and or metastatic disease with recommended short interval follow-up are not an exclusion factor for study participation. The recommended follow-up imaging for such findings should have no bearing on the imaging schedule in this protocol, and this research protocol imaging should NOT serve as an official follow-up scan for such findings.
    • * Patients who are pregnant or breastfeeding.
    • * Premenopausal persons of childbearing potential must have a negative pregnancy test within 14 days of enrollment. If women are not of childbearing potential as defined by women who are menopausal female or has had a hysterectomy, bilateral oophorectomy, or medically-documented ovarian failure, they will not require a pregnancy test. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
Ages Eligible for Study: 18 Years to N/A (ADULT, OLDER_ADULT)
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No

🗓️ Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

  • First Submitted 7 December 2022
  • First Submitted that Met QC Criteria 11 January 2023
  • First Posted 20 January 2023

Study Record Updates

  • Last Update Submitted that Met QC Criteria 13 June 2024
  • Last Update Posted 14 June 2024
  • Last Verified June 2024